Last updated: October 04, 2026

Application No. 17/273,680

Methods of Treating Cancer

Non-Final OA

Filed

Mar 04, 2021

Priority

Sep 04, 2018 — provisional 62/726,826 +1 more

Examiner

LANDSMAN, ROBERT S

Art Unit

1647

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Tesaro Inc.

OA Round

3 (Non-Final)

Interview Optional

— +13.0% interview lift. Interview lift (+13.0%) is below the 15.0% threshold. A written response is recommended.

Based on 1276 resolved cases, 2023–2026

Examiner Intelligence

LANDSMAN, ROBERT S View full profile →

Grants 81% — above average

Career Allowance Rate

1038 granted / 1276 resolved

+21.3% vs TC avg

Moderate +13% lift

Without

With

+13.0%

Interview Lift

resolved cases with interview

Fast prosecutor

2y 2m

Avg Prosecution

59 currently pending

Career history

1302

Total Applications

across all art units

Statute-Specific Performance

§101

3.6%

-36.4% vs TC avg

§103

19.6%

-20.4% vs TC avg

§102

13.3%

-26.7% vs TC avg

§112

40.3%

+0.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1276 resolved cases

Prosecution Timeline

Mar 04, 2021

Application Filed

Jan 23, 2024

Non-Final Rejection mailed

May 29, 2024

Response Filed

Apr 18, 2025

Final Rejection mailed

Sep 18, 2025

Request for Continued Examination

Sep 25, 2025

Response after Non-Final Action

Jul 29, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/024,143

Patent 12747297

BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT AND INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT, AND USE THEREOF

3y 7m to grant Granted Sep 29, 2026

18/246,756

Patent 12742005

Antibody Binding to Human IL-33, Preparation Method Therefor, and Use Thereof

3y 6m to grant Granted Sep 22, 2026

18/017,167

Patent 12734246

ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF

3y 7m to grant Granted Sep 15, 2026

18/032,084

Patent 12735473

COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS

3y 5m to grant Granted Sep 15, 2026

18/033,337

Patent 12735508

BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR ALPHA AND TRANSFORMING GROWTH FACTOR BETA AND USES THEREOF

3y 4m to grant Granted Sep 15, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

81%

Grant Probability

94%

With Interview (+13.0%)

2y 2m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 1276 resolved cases by this examiner. Grant probability derived from career allowance rate.